• by admin
• (0) Comments

Indian AI Research Body (IAIRO) to Support Healthcare & Cross-Sector Innovation

A new Indian AI Research Organisation (IAIRO)will be established in GIFT City as a public-private initiative to advance AI R&D across sectors including healthcare. With an initial budget of ₹300 crore and industry support from the Indian Pharmaceutical Alliance, IAIRO aims to accelerate multidisciplinary AI applications in diagnostics, drug discovery, policy research, and more.

News Source: Times of India (The Times of India)

Helus Pharma Begins Trading on Nasdaq After Mental-Health Innovation Push

HELUS Pharma, a clinical-stage pharmaceutical company focused on therapeutic innovation in mental health, has commenced trading on the Nasdaq stock exchangeunder the ticker HELP. The move follows advancement of its pipeline targeting conditions such as depression, anxiety and related disorders.

News Source: Business Wire / Helus Pharma (Business Wire)

---

Indian Pharma Generics Opportunity Widens with Semaglutide Patent Expiry

The impending patent expiry of semaglutide — a leading therapy for diabetes and obesity — is expected to open a Rs 50 billion opportunityfor Indian generic manufacturers over the next 12–15 months. Companies are preparing capabilities to launch more affordable versions in India, emerging markets, and select regulated regions once exclusivity lapses.

News Source: Times of India (The Times of India)

---

Indian Government PLI Scheme Continues to Support Bulk Drug Manufacturing

India’s renewed Production Linked Incentive (PLI) scheme for bulk drugs has reopened applications targeting key APIs such as Meropenem and Ritonavir, reinforcing the country’s strategy to strengthen domestic API production and reduce import dependence for critical medicines.

News Source: India Briefing (India Briefing)

---

New International Allergy Guidelines Could Save Lives

A global expert panel has released new recommendations for epinephrine use in acute allergic emergencies, designed to standardise emergency response for anaphylaxis — including training for caregivers and bystanders in recognizing severe reactions early.

News Source: Medical Dialogues (via video bulletin) (Medical Dialogues)

---

📌 Daily Pulse Insight — Why This Matters

✔ Capital markets meet healthcare innovation: Helus Pharma’s Nasdaq debut highlights growing investor interest in mental-health drug development.

✔ India’s pharma manufacturing strength is pivoting toward high-opportunity generics with the semaglutide patent expiry — a video market worth billions.

✔ AI for health is becoming mainstream: With IAIRO, India aims to fuse tech with life sciences innovation.

✔ Supply chain resilience keeps rising: PLI support for APIs signals long-term industrial strategy.

✔ Global care standards evolve: New epinephrine guidelines could reduce preventable deaths from anaphylaxis.

---

✨ Follow Daily Pulse for concise, credible healthcare & pharma insights every day — with context that matters. #DailyPulse #HealthcareNews #PharmaUpdates #MentalHealthDrugs #AIinHealthcare #IndiaPharma #GlobalHealth

---

Disclaimer: The views and opinions expressed in this interview are those of the author and do not reflect the official position of any medical body or organization. 
The author is not a medical doctor; however, the insights shared are based on over a decade of working experience in the healthcare sector start-ups. 
Readers should consult with a qualified healthcare professional for medical advice or information related to their specific situation.

Please follow our page Aristocrat Media for more updates 
For Enquiries connect us on:
marketing@aristocrat-media.com